糖尿病保健 TNDM 深 滬
已收盤 05-08 16:00:00 美东时间
15.48
-2.990
-16.19%
華盛通- 最 高20.03
- 今 開20.00
- 成交量 753.26万股
- 最 低 15.44
- 昨 收 18.47
- 總市值 10.60亿
- 52周最高 29.65
- 市盈率 靜 --
- 換手率 11.00%
- 52周最低 9.98
- 委 比 -76.18%
- 總股本 6850.42万
- 歷史最高 302.50
- 量 比 3.40
- 振 幅 24.85%
- 歷史最低 2.14
- 每 手 1
- 風險率 3.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | 糖尿病保健 2026财年Q1营收2.47亿美元，同比增长5.5%；归母净利润亏损0.20亿美元，同比亏损缩窄84.4%
华盛资讯5月8日讯，糖尿病保健公布2026财年Q1业绩，公司Q1营收2.47亿美元，同比增长5.5%，归母净利润亏损0.20亿美元，同比亏损缩窄84.4%。
05-08 13:51
Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q1 financial results.
Tandem Diabetes Care shares are trading higher after the company reported bette...
05-08 05:21
财报速睇 | 糖尿病保健 2026财年Q1营收2.47亿美元，同比增长5.6%；归母净利润亏损0.20亿美元，同比亏损缩窄84.7%
华盛资讯5月8日讯，糖尿病保健公布2026财年Q1业绩，公司Q1营收2.47亿美元，同比增长5.6%，归母净利润亏损0.20亿美元，同比亏损缩窄84.7%。
05-08 04:56
Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate.
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 54.55 percent increase over losses of $(0.67) per share
05-08 04:34
FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps
FDA flags Class I recall for Tandem Mobi insulin pumps tied to software glitch that may halt insulin delivery, with four injuries reported.
04-25 02:18
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
TD Cowen Maintains Buy on Tandem Diabetes Care, Raises Price Target to $28
TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $25 to $28.
04-20 22:45
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Goldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25
Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $28 to $25.
04-10 01:50
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising competition and past share losses.
04-01 22:15
